Eikon Adds Nearly $351M to Conquer Phase III Development in Melanoma
Source: BioSpace, February 2025
Eikon’s lead candidate, EIK1001, is being tested for advanced melanoma. The candidate is currently in late-stage development, which the biotech will fund using Wednesday’s series D raise.
Eikon Therapeutics raked in $350.7 million in a series D fundraising round announced Wednesday. That is money the biotech will put to good use as its lead candidate EIK1001 enters Phase III trials for advanced melanoma.
Of note, Eikon’s news release explicitly announced the “initial closing” of its series D—which suggests that potential funders still have the chance to join the round later on. Indeed, in an interview with Endpoints News, CEO Roger Perlmutter said he anticipates other investors will pitch in later this year.